Rivian Faces Biggest Short-Term Threat: What Investors Need to Know
Rivian has captured imaginations—and capital. But the next 12 months will test its ability to scale, control costs, a...
A ten-year comparison of Aristocrats ETFs highlights performance patterns, dividend consistency, and growth trajectory to aid selection.
27,377 articlesRivian has captured imaginations—and capital. But the next 12 months will test its ability to scale, control costs, a...
Divisadero Street Capital Management upped its stake in Dave (DAVE), fueling questions about a potential buying oppor...
A memory-focused rally has vaulted a mid-cap equipment maker by about 90% in 2.5 months, shifting attention away from...
Lululemon is set to report its Q1 results tonight as margins, growth mix, and international exposure take center stag...
Markets surge as investors debate mega-valuations tied to founder-led tech giants. This piece breaks down what everyd...
Billionaire investor Mark Cuban warns popular bets could quietly erode wealth as funding costs rise and consumer conf...
When a blue-chip name like Microsoft moves, it can shake nerves and portfolios. This guide explains why microsoft sto...
New disclosures reveal a mixed picture: five Fortune 500 holdings drew public commentary in 2026, while two media nam...
Biotech shares retreat as Moderna slides 11% and ImmunityBio falls, with Sarepta also sinking amid a broad market rot...
Meta and Microsoft posted strong results, yet insider selling patterns diverged sharply. Meta's executives have been ...
NVIDIA is expected to report a $65.7 billion Q4 revenue figure as investors weigh margin recovery against AI-driven d...
O-I Glass has climbed about 17% over the past year, even as a large fund unloaded roughly $80 million worth of stock....